Efficacy of GSK Biologicals' Candidate Malaria Vaccine (257049) Against Malaria Disease Caused by P. Falciparum Infection in Infants and Children in Africa

Trial Profile

Efficacy of GSK Biologicals' Candidate Malaria Vaccine (257049) Against Malaria Disease Caused by P. Falciparum Infection in Infants and Children in Africa

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs GSK 257049 (Primary) ; AS01B; Hib-DTP-hepatitis B vaccine; Meningococcal vaccine group C conjugate; Poliovirus vaccine live oral; Rabies vaccine
  • Indications Diphtheria; Falciparum malaria; Haemophilus infections; Hepatitis B; Malaria; Meningococcal group C infections; Pertussis; Pneumonia; Poliomyelitis; Rabies; Tetanus
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Oct 2015 Results published in the New England Journal of Medicine
    • 24 Jul 2015 According to a Glaxo SmithKline media release, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive scientific opinion for its malaria candidate vaccine Mosquirix, also known as RTS,S, in children aged 6 weeks to 17 months.
    • 04 Jul 2015 Results published in the Lancet.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top